SYM FINANCIAL Corp Invests $522,000 in Stryker Corporation $SYK

SYM FINANCIAL Corp purchased a new stake in shares of Stryker Corporation (NYSE:SYK) during the 3rd quarter, Holdings Channel reports. The fund purchased 1,411 shares of the medical technology company’s stock, valued at approximately $522,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Mid American Wealth Advisory Group Inc. bought a new position in shares of Stryker in the 2nd quarter valued at about $26,000. Clayton Financial Group LLC bought a new stake in shares of Stryker during the third quarter worth approximately $26,000. Elevation Point Wealth Partners LLC acquired a new position in Stryker in the second quarter valued at approximately $28,000. Sachetta LLC boosted its stake in Stryker by 58.7% in the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after acquiring an additional 27 shares during the last quarter. Finally, Kilter Group LLC acquired a new stake in Stryker during the 2nd quarter worth $29,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently issued reports on SYK. UBS Group set a $408.00 price target on Stryker in a research report on Monday, October 13th. Needham & Company LLC restated a “buy” rating and set a $448.00 target price on shares of Stryker in a research report on Friday, November 14th. Truist Financial cut their price target on shares of Stryker from $400.00 to $392.00 and set a “hold” rating on the stock in a research report on Thursday, December 18th. Barclays boosted their price objective on shares of Stryker from $443.00 to $453.00 and gave the company an “overweight” rating in a report on Wednesday, October 22nd. Finally, The Goldman Sachs Group set a $399.00 target price on shares of Stryker in a report on Friday, January 9th. Twelve research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $425.94.

Insiders Place Their Bets

In other Stryker news, CFO Preston Wendell Wells sold 165 shares of Stryker stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $365.88, for a total value of $60,370.20. Following the sale, the chief financial officer owned 6,694 shares of the company’s stock, valued at $2,449,200.72. This trade represents a 2.41% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO William E. Berry, Jr. sold 1,953 shares of the stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $365.49, for a total value of $713,801.97. Following the transaction, the chief accounting officer owned 2,833 shares of the company’s stock, valued at approximately $1,035,433.17. The trade was a 40.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 522,118 shares of company stock worth $185,381,932. Corporate insiders own 5.90% of the company’s stock.

Stryker News Roundup

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly beat: Stryker reported adjusted Q4 EPS $4.47 and revenue $7.17B, topping consensus on both measures — a clear near‑term positive for revenue and profitability trends. Stryker (SYK) Surpasses Q4 Earnings and Revenue Estimates
• Positive Sentiment: Raised profit outlook: Management raised its full‑year profit forecast, citing strong implant and capital product demand — a catalyst for forward earnings expectations. Stryker raises annual profit forecast on strong sales for medical devices
• Positive Sentiment: Solid full‑year momentum and guidance: FY2025 adjusted EPS and margins expanded (adjusted EPS $13.63; adjusted operating margin +100 bps year) and management guided 2026 organic net‑sales growth ~8.0%–9.5% with adjusted EPS $14.90–$15.10 — supports medium‑term upside. Stryker reports 2025 operating results and 2026 outlook
• Neutral Sentiment: Analyst/street context: Several firms maintain positive ratings (e.g., Piper Sandler reaffirmed a Buy), and sell‑side median targets remain well above the current price — supports sentiment but may already be priced in. Piper Sandler Remains a Buy on Stryker (SYK)
• Neutral Sentiment: Conference call / details ahead: Management held an earnings call and provided granular segment math and non‑GAAP reconciliations — useful for modeling but unlikely to shift the stock absent new guidance tweaks. Press release & conference details
• Negative Sentiment: Mixed segment dynamics: MedSurg & Neuro showed double‑digit growth, but spinal implants and some orthopaedics subcategories remain weak or volatile — a potential drag on sustained top‑line upside. Stryker Reports Strong Q4 and Full-Year 2025 Results
• Negative Sentiment: One‑offs and legacy charges: Prior goodwill impairments, tax adjustments and other special items still affect GAAP comparisons and introduce modeling uncertainty — some investors may be trimming positions until recurring earnings visibility is clearer. Full release: reconciliations and note on adjustments
• Negative Sentiment: Valuation and profit‑taking risk: SYK trades at a premium P/E (~46 on reported metrics) and recent insider selling activity may encourage short‑term profit‑taking despite the beat. Analyst comparison & metrics

Stryker Price Performance

NYSE SYK opened at $354.39 on Friday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.13 and a current ratio of 1.85. The stock has a market cap of $135.52 billion, a price-to-earnings ratio of 46.57, a PEG ratio of 2.29 and a beta of 0.89. The business has a 50 day simple moving average of $359.38 and a 200 day simple moving average of $371.95. Stryker Corporation has a 52-week low of $329.16 and a 52-week high of $404.87.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, beating analysts’ consensus estimates of $4.40 by $0.07. Stryker had a net margin of 12.07% and a return on equity of 24.07%. The firm had revenue of $7.17 billion for the quarter, compared to analyst estimates of $7.12 billion. During the same quarter in the previous year, the firm posted $4.01 earnings per share. The business’s revenue was up 11.4% on a year-over-year basis. Analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Wednesday, December 31st will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Wednesday, December 31st. This is a boost from Stryker’s previous quarterly dividend of $0.84. Stryker’s dividend payout ratio (DPR) is currently 46.25%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.